請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/91332
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張瑞峰 | zh_TW |
dc.contributor.advisor | Ruey-Feng Chang | en |
dc.contributor.author | 傅家保 | zh_TW |
dc.contributor.author | Chia-Po Fu | en |
dc.date.accessioned | 2023-12-20T16:31:55Z | - |
dc.date.available | 2023-12-21 | - |
dc.date.copyright | 2023-12-20 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-12-07 | - |
dc.identifier.citation | 1. Uday Muddebihal M. LM, K.S.Hanumanthaiah, Yasaswini H., , Manjunath K. AS: Surgical anatomy of thyroid and incidence of malignancy in solitary nodule of thyroid. International Surgery Journal 2016, 3(2):7.
2. Nachiappan AC, Metwalli ZA, Hailey BS, Patel RA, Ostrowski ML, Wynne DM: The thyroid: review of imaging features and biopsy techniques with radiologic-pathologic correlation. Radiographics 2014, 34(2):276-293. 3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M et al: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26(1):1-133. 4. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, Paschke R, Valcavi R, Vitti P, Nodules AAATFoT: American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules--2016 Update. Endocr Pract 2016, 22(5):622-639. 5. Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, Cronan JJ, Beland MD, Desser TS, Frates MC et al: ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol 2017, 14(5):587-595. 6. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L: European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J 2017, 6(5):225-237. 7. Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, Lim HK, Moon WJ, Na DG, Park JS et al: Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol 2016, 17(3):370-395. 8. Grani G, Lamartina L, Cantisani V, Maranghi M, Lucia P, Durante C: Interobserver agreement of various thyroid imaging reporting and data systems. Endocr Connect 2018, 7(1):1-7. 9. Choi SH, Kim EK, Kwak JY, Kim MJ, Son EJ: Interobserver and intraobserver variations in ultrasound assessment of thyroid nodules. Thyroid 2010, 20(2):167-172. 10. Trimboli P, Treglia G, Sadeghi R, Romanelli F, Giovanella L: Reliability of real-time elastography to diagnose thyroid nodules previously read at FNAC as indeterminate: a meta-analysis. Endocrine 2015, 50(2):335-343. 11. Azizi G, Keller J, Lewis M, Puett D, Rivenbark K, Malchoff C: Performance of elastography for the evaluation of thyroid nodules: a prospective study. Thyroid 2013, 23(6):734-740. 12. Welker MJ, Orlov D: Thyroid nodules. Am Fam Physician 2003, 67(3):559-566. 13. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L: Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med 2016, 375(7):614-617. 14. Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP: Systematic Review of Trends in the Incidence Rates of Thyroid Cancer. Thyroid 2016, 26(11):1541-1552. 15. Hagag P, Strauss S, Weiss M: Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid 1998, 8(11):989-995. 16. Brito JP, Gionfriddo MR, Al Nofal A, Boehmer KR, Leppin AL, Reading C, Callstrom M, Elraiyah TA, Prokop LJ, Stan MN et al: The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 2014, 99(4):1253-1263. 17. Wu HH, Jones JN, Osman J: Fine-needle aspiration cytology of the thyroid: ten years experience in a community teaching hospital. Diagn Cytopathol 2006, 34(2):93-96. 18. Hegedus L: Clinical practice. The thyroid nodule. N Engl J Med 2004, 351(17):1764-1771. 19. Price DC: Radioisotopic evaluation of the thyroid and the parathyroids. Radiol Clin North Am 1993, 31(5):991-1015. 20. Meller J, Becker W: The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound. Eur J Nucl Med Mol Imaging 2002, 29 Suppl 2:S425-438. 21. Robbins RJ, Schlumberger MJ: The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005, 46 Suppl 1:28S-37S. 22. Loevinger R BT, Watson EE: MIRD Primer for Absorbed Dose Calculations. New York: Society of Nuclear Medicine 1988. 23. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer T: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154(6):787-803. 24. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19(11):1167-1214. 25. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM: Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol 2008, 191(6):1785-1794. 26. Aide N, Heutte N, Rame JP, Rousseau E, Loiseau C, Henry-Amar M, Bardet S: Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. J Clin Endocrinol Metab 2009, 94(6):2075-2084. 27. Avram AM: Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med 2012, 53(5):754-764. 28. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, Strauss HW, Larson SM, Schoder H: The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med 2010, 51(9):1361-1367. 29. Phan TT, Jager PL, van Tol KM, Links TP: Thyroid cancer imaging. Cancer Treat Res 2004, 122:317-343. 30. Alberico RA, Husain SH, Sirotkin I: Imaging in head and neck oncology. Surg Oncol Clin N Am 2004, 13(1):13-35. 31. Seiberling KA, Dutra JC, Grant T, Bajramovic S: Role of intrathyroidal calcifications detected on ultrasound as a marker of malignancy. Laryngoscope 2004, 114(10):1753-1757. 32. Khoo ML, Asa SL, Witterick IJ, Freeman JL: Thyroid calcification and its association with thyroid carcinoma. Head Neck 2002, 24(7):651-655. 33. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S: US Features of thyroid malignancy: pearls and pitfalls. Radiographics 2007, 27(3):847-860; discussion 861-845. 34. Komolafe F: Radiological patterns and significance of thyroid calcification. Clin Radiol 1981, 32(5):571-575. 35. Wang N, Xu Y, Ge C, Guo R, Guo K: Association of sonographically detected calcification with thyroid carcinoma. Head Neck 2006, 28(12):1077-1083. 36. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD, Jr., Larsen PR, Marqusee E et al: Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 2006, 91(9):3411-3417. 37. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, Kim J, Kim HS, Byun JS, Lee DH et al: Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology 2008, 247(3):762-770. 38. Koike E, Noguchi S, Yamashita H, Murakami T, Ohshima A, Kawamoto H, Yamashita H: Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 2001, 136(3):334-337. 39. Margolin FR, Winfield J, Steinbach HL: Patterns of thyroid calcification. Roentgenologic-histologic study of excised specimens. Invest Radiol 1967, 2(3):208-212. 40. Fukatsu H, Makino N, Kodama Y, Ikeda M, Ishigaki T, Sakuma S: Evaluation of thyroid calcification using computed radiography with image plate. Eur J Radiol 1989, 9(1):22-28. 41. Taki S, Terahata S, Yamashita R, Kinuya K, Nobata K, Kakuda K, Kodama Y, Yamamoto I: Thyroid calcifications: sonographic patterns and incidence of cancer. Clin Imaging 2004, 28(5):368-371. 42. Chammas MC, de Araujo Filho VJ, Moyses RA, Brescia MD, Mulatti GC, Brandao LG, Cerri GG, Ferraz AR: Predictive value for malignancy in the finding of microcalcifications on ultrasonography of thyroid nodules. Head Neck 2008, 30(9):1206-1210. 43. Moschetta M, Ianora AA, Testini M, Vacca M, Scardapane A, Angelelli G: Multidetector computed tomography in the preoperative evaluation of retrosternal goiters: a useful procedure for patients for whom magnetic resonance imaging is contraindicated. Thyroid 2010, 20(2):181-187. 44. Ishigaki S, Shimamoto K, Satake H, Sawaki A, Itoh S, Ikeda M, Ishigaki T, Imai T: Multi-slice CT of thyroid nodules: comparison with ultrasonography. Radiat Med 2004, 22(5):346-353. 45. Soler ZM, Hamilton BE, Schuff KG, Samuels MH, Cohen JI: Utility of computed tomography in the detection of subclinical nodal disease in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2008, 134(9):973-978. 46. Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG: Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid 2008, 18(4):411-418. 47. Wu CW, Dionigi G, Lee KW, Hsiao PJ, Paul Shin MC, Tsai KB, Chiang FY: Calcifications in thyroid nodules identified on preoperative computed tomography: patterns and clinical significance. Surgery 2012, 151(3):464-470. 48. Park CH, Rothermel FJ, Judge DM: Unusual calcification in mixed papillary and follicular carcinoma of the thyroid gland. Radiology 1976, 119(3):554. 49. Vescini F, Di Gaetano P, Vigna E, Pascoli A, Cacciari M: Anaplastic thyroid carcinoma in a 49 year-old woman with a long-standing goiter. A case report. Minerva Endocrinol 2000, 25(3-4):81-83. 50. Padovani RP, Kasamatsu TS, Nakabashi CC, Camacho CP, Andreoni DM, Malouf EZ, Marone MM, Maciel RM, Biscolla RP: One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. Thyroid 2012, 22(9):926-930. 51. Miyakoshi A, Dalley RW, Anzai Y: Magnetic resonance imaging of thyroid cancer. Top Magn Reson Imaging 2007, 18(4):293-302. 52. Schellinger PD, Meinck HM, Thron A: Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999, 44(3):275-281. 53. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J et al: High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 2005, 90(2):779-788. 54. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G et al: Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007, 92(11):4185-4190. 55. Metere A, Aceti V, Giacomelli L: The surgical management of locally advanced well-differentiated thyroid carcinoma: changes over the years according to the AJCC 8th edition Cancer Staging Manual. Thyroid Res 2019, 12:10. 56. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW: The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007, 3(2):112-121. 57. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI et al: Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009, 94(4):1310-1316. 58. Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY, Sun F, Luo XG: Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 2009, 30(8):639-650. 59. Caetano R, Bastos CR, de Oliveira IA, da Silva RM, Fortes CP, Pepe VL, Reis LG, Braga JU: Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis. Head Neck 2016, 38(2):316-327. 60. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M: Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001, 42(1):71-76. 61. Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F: Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 2003, 149(4):293-300. 62. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schafers M, Schober O: Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998, 383(2):160-163. 63. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM: Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006, 91(2):498-505. 64. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, Lumbroso J, Baudin E, Caillou B, Bidart JM et al: Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011, 18(1):159-169. 65. Deandreis D, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, Deschamps F, Rao P, Schlumberger M, de Baere T: Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 2011, 258(1):270-276. 66. Van den Bruel A, Maes A, De Potter T, Mortelmans L, Drijkoningen M, Van Damme B, Delaere P, Bouillon R: Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002, 87(4):1517-1520. 67. Kim JM, Ryu JS, Kim TY, Kim WB, Kwon GY, Gong G, Moon DH, Kim SC, Hong SJ, Shong YK: 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 2007, 92(5):1630-1634. 68. Lamartina L, Deandreis D, Durante C, Filetti S: ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol 2016, 175(5):R185-202. 69. Stangierski A, Wolinski K, Czepczynski R, Czarnywojtek A, Lodyga M, Wyszomirska A, Janicka-Jedynska M, Baczyk M, Ruchala M: The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination. PLoS One 2014, 9(10):e109612. 70. Pattison DA, Bozin M, Gorelik A, Hofman MS, Hicks RJ, Skandarajah A: (18)F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. J Nucl Med 2018, 59(5):749-755. 71. Vaish R, Venkatesh R, Chaukar DA, Deshmukh AD, Purandare NC, D'Cruz A K: Positron emission tomography thyroid incidentaloma: Is it different in Indian subcontinent? Indian J Cancer 2016, 53(1):186-189. 72. Mirza AA, Pai E, Srinivas KG, Amarendra S, Gopinath KS: Diagnostic Dilemma in a Thyroid Incidentaloma: Second Primary versus Metastatic Nodule? J Clin Diagn Res 2016, 10(6):PD10-12. 73. Elzein S, Ahmed A, Lorenz E, Balasubramanian SP: Thyroid incidentalomas on PET imaging--evaluation of management and clinical outcomes. Surgeon 2015, 13(2):116-120. 74. Katz SC, Shaha A: PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008, 207(2):259-264. 75. Kaliszewski K, Diakowska D, Zietek M, Knychalski B, Aporowicz M, Sutkowski K, Wojtczak B: Thyroid incidentaloma as a "PAIN" phenomenon- does it always require surgery? Medicine (Baltimore) 2018, 97(49):e13339. 76. Ahn HS, Lee JB, Seo M, Park SH, Choi BI: Distinguishing benign from malignant thyroid nodules using thyroid ultrasonography: utility of adding superb microvascular imaging and elastography. Radiol Med 2018, 123(4):260-270. 77. Wilhelm S: Evaluation of thyroid incidentaloma. Surg Clin North Am 2014, 94(3):485-497. 78. Nikiforov YE BZ, Belge G, Chan JKC, Derwahl KM, Evans HL, Fagin JA, , Ghossein RA LR, Oriola J, Osamura RY, Paschke R, Sobrinho Simoes M. Follicular , adenoma. In: Lloyd RV OR, Kloppel G, Rosai J, editors.: International Agency for Research on Cancer. WHO Classification of Tumours of Endocrine Organs 4th ed 2017:3. 79. Hegedus L, Bonnema SJ, Bennedbaek FN: Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003, 24(1):102-132. 80. Hoang JK, Nguyen XV: Understanding the Risks and Harms of Management of Incidental Thyroid Nodules: A Review. JAMA Otolaryngol Head Neck Surg 2017, 143(7):718-724. 81. Choi N, Moon WJ, Kim HY, Roh HG, Choi JW: Thyroid incidentaloma detected by time-resolved magnetic resonance angiography at 3T: prevalence and clinical significance. Korean J Radiol 2012, 13(3):275-282. 82. Lim HK, Park ST, Ha H, Choi SY: Thyroid Nodules Detected by Contrast-Enhanced Magnetic Resonance Angiography: Prevalence and Clinical Significance. PLoS One 2016, 11(2):e0149811. 83. Kim K, Emoto N, Mishina M, Okada S, Isu T, Yoshida D, Kobayashi S, Teramoto A: Incidental detection of thyroid nodules at magnetic resonance imaging of the cervical spine. Neurol Med Chir (Tokyo) 2013, 53(2):77-81. 84. Vander JB, Gaston EA, Dawber TR: The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968, 69(3):537-540. 85. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA: The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977, 7(6):481-493. 86. Mortensen JD, Woolner LB, Bennett WA: Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955, 15(10):1270-1280. 87. Tan GH, Gharib H: Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997, 126(3):226-231. 88. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P et al: Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997, 61(5):1123-1130. 89. Capon F, Tacconelli A, Giardina E, Sciacchitano S, Bruno R, Tassi V, Trischitta V, Filetti S, Dallapiccola B, Novelli G: Mapping a dominant form of multinodular goiter to chromosome Xp22. Am J Hum Genet 2000, 67(4):1004-1007. 90. Carle A, Krejbjerg A, Laurberg P: Epidemiology of nodular goitre. Influence of iodine intake. Best Pract Res Clin Endocrinol Metab 2014, 28(4):465-479. 91. Huang PC, Tsai CH, Liang WY, Li SS, Huang HB, Kuo PL: Early Phthalates Exposure in Pregnant Women Is Associated with Alteration of Thyroid Hormones. PLoS One 2016, 11(7):e0159398. 92. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT: Executive Summary to EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev 2015, 36(6):593-602. 93. Knudsen N, Brix TH: Genetic and non-iodine-related factors in the aetiology of nodular goitre. Best Pract Res Clin Endocrinol Metab 2014, 28(4):495-506. 94. Krejbjerg A, Bjergved L, Pedersen IB, Knudsen N, Jorgensen T, Perrild H, Ovesen L, Rasmussen LB, Laurberg P: Thyroid nodules in an 11-year DanThyr follow-up study. J Clin Endocrinol Metab 2014, 99(12):4749-4757. 95. Delange F, de Benoist B, Pretell E, Dunn JT: Iodine deficiency in the world: where do we stand at the turn of the century? Thyroid 2001, 11(5):437-447. 96. Knudsen N, Bulow I, Jorgensen T, Laurberg P, Ovesen L, Perrild H: Goitre prevalence and thyroid abnormalities at ultrasonography: a comparative epidemiological study in two regions with slightly different iodine status. Clin Endocrinol (Oxf) 2000, 53(4):479-485. 97. Knudsen N, Perrild H, Christiansen E, Rasmussen S, Dige-Petersen H, Jorgensen T: Thyroid structure and size and two-year follow-up of solitary cold thyroid nodules in an unselected population with borderline iodine deficiency. Eur J Endocrinol 2000, 142(3):224-230. 98. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F et al: The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995, 43(1):55-68. 99. Studer H, Peter HJ, Gerber H: Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth. Endocr Rev 1989, 10(2):125-135. 100. Medeiros-Neto G KM: Iodine deficiency disorders. In: Jameson JL, DeGroot LJ (eds) Endocrinology, 6th edn Elsevier, Philadelphia 2010:17. 101. Knobel M M-NG: Pediatric aspects of thyroid function and iodine. In: Krassas GE, Rivkees SA, Kiess W (eds) Diseases of the thyroid in childhood and adolescence Pediatr Adolesc Med, Karger, Basel 2007:14. 102. Knobel M, Bisi H, de Araujo Peres C, Medeiros-Neto G: Studies on functional and morphological aspects in human multinodular simple goiter tissues. Endocr Pathol 1993, 4(4):205-214. 103. Knobel M: Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters. J Endocrinol Invest 2016, 39(4):357-373. 104. Furlanetto TW, Nguyen LQ, Jameson JL: Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. Endocrinology 1999, 140(12):5705-5711. 105. Brix TH, Hansen PS, Kyvik KO, Hegedus L: Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med 2000, 160(5):661-666. 106. Knudsen N, Laurberg P, Perrild H, Bulow I, Ovesen L, Jorgensen T: Risk factors for goiter and thyroid nodules. Thyroid 2002, 12(10):879-888. 107. Spinos N, Terzis G, Crysanthopoulou A, Adonakis G, Markou KB, Vervita V, Koukouras D, Tsapanos V, Decavalas G, Kourounis G et al: Increased frequency of thyroid nodules and breast fibroadenomas in women with uterine fibroids. Thyroid 2007, 17(12):1257-1259. 108. Knudsen N, Bulow I, Laurberg P, Perrild H, Ovesen L, Jorgensen T: Low goitre prevalence among users of oral contraceptives in a population sample of 3712 women. Clin Endocrinol (Oxf) 2002, 57(1):71-76. 109. Cappelli C, Castellano M, Pirola I, De Martino E, Gandossi E, Delbarba A, Salvi A, Rosei EA: Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment. Clin Endocrinol (Oxf) 2008, 68(1):16-21. 110. Gaitan E, Cooksey RC, Legan J, Lindsay RH, Ingbar SH, Medeiros-Neto G: Antithyroid effects in vivo and in vitro of babassu and mandioca: a staple food in goiter areas of Brazil. Eur J Endocrinol 1994, 131(2):138-144. 111. Suzuki H, Higuchi T, Sawa K, Ohtaki S, Horiuchi Y: "Endemic coast goitre" in Hokkaido, Japan. Acta Endocrinol (Copenh) 1965, 50(2):161-176. 112. Lazarus JH: Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009, 23(6):723-733. 113. Boas M, Main KM, Feldt-Rasmussen U: Environmental chemicals and thyroid function: an update. Curr Opin Endocrinol Diabetes Obes 2009, 16(5):385-391. 114. Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R: Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005, 26(4):504-524. 115. Brix TH, Kyvik KO, Hegedus L: Major role of genes in the etiology of simple goiter in females: a population-based twin study. J Clin Endocrinol Metab 1999, 84(9):3071-3075. 116. Hansen PS, Brix TH, Bennedbaek FN, Bonnema SJ, Kyvik KO, Hegedus L: Genetic and environmental causes of individual differences in thyroid size: a study of healthy Danish twins. J Clin Endocrinol Metab 2004, 89(5):2071-2077. 117. Neumann S, Willgerodt H, Ackermann F, Reske A, Jung M, Reis A, Paschke R: Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab 1999, 84(10):3750-3756. 118. Cooke MS, Evans MD, Dizdaroglu M, Lunec J: Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003, 17(10):1195-1214. 119. Rentsch H, Studer H, Frauchiger B, Siebenhuner L: Topographical heterogeneity of basal and thyrotropin-stimulated adenosine 3'5'-monophosphate in human nodular goiter. J Clin Endocrinol Metab 1981, 53(3):514-521. 120. Abs R, Stevenaert A, Beckers A: Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible cause--effect relationship. Eur J Endocrinol 1994, 131(4):355-358. 121. Van Sande J, Parma J, Tonacchera M, Swillens S, Dumont J, Vassart G: Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 1995, 80(9):2577-2585. 122. Bjergved L, Jorgensen T, Perrild H, Carle A, Cerqueira C, Krejbjerg A, Laurberg P, Ovesen L, Bulow Pedersen I, Banke RL et al: Predictors of change in serum TSH after iodine fortification: an 11-year follow-up to the DanThyr study. J Clin Endocrinol Metab 2012, 97(11):4022-4029. 123. Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL: Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 1995, 4(2):113-121. 124. Foley TP, Jr.: Goiter in adolescents. Endocrinol Metab Clin North Am 1993, 22(3):593-606. 125. Alexander EK, Hurwitz S, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Larsen PR, Marqusee E: Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 2003, 138(4):315-318. 126. Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM et al: Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. J Clin Endocrinol Metab 2017, 102(12):4642-4647. 127. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M et al: The natural history of benign thyroid nodules. JAMA 2015, 313(9):926-935. 128. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Marqusee E: Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002, 87(11):4924-4927. 129. Soelberg KK, Bonnema SJ, Brix TH, Hegedus L: Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 2012, 22(9):918-925. 130. Matheus MV, Kowdley GC: Pemberton's Sign in a Patient With Multinodular Goiter. Am Surg 2021, 87(12):2003-2005. 131. Davies L, Welch HG: Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014, 140(4):317-322. 132. Ahn HS, Kim HJ, Welch HG: Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. N Engl J Med 2014, 371(19):1765-1767. 133. Ito Y, Nikiforov YE, Schlumberger M, Vigneri R: Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol 2013, 9(3):178-184. 134. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM: Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017, 317(13):1338-1348. 135. Paschou SA, Vryonidou A, Goulis DG: Thyroid nodules: Alpha guide to assessment, treatment and follow-up. Maturitas 2017, 96:1-9. 136. Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, Krane JF, Barletta JA, Kim MI, Larsen PR et al: The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk. J Clin Endocrinol Metab 2015, 100(12):4434-4440. 137. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R et al: Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004, 89(7):3402-3407. 138. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA, Committee for Neck Dissection Classification AH, Neck S: Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 2008, 134(5):536-538. 139. Nou E, Kwong N, Alexander LK, Cibas ES, Marqusee E, Alexander EK: Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. J Clin Endocrinol Metab 2014, 99(2):510-516. 140. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH: The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 2007, 142(6):837-844; discussion 844 e831-833. 141. Cross P CA, Giles T, Johnson S, Kocjan G, Poller D, Stephenson T. : Guidance on the Reporting of Thyroid Cytology Specimens, 2nd ed. London: Royal College of Pathologists 2016. 142. Meko JB, Norton JA: Large cystic/solid thyroid nodules: a potential false-negative fine-needle aspiration. Surgery 1995, 118(6):996-1003; discussion 1003-1004. 143. Carrillo JF, Frias-Mendivil M, Ochoa-Carrillo FJ, Ibarra M: Accuracy of fine-needle aspiration biopsy of the thyroid combined with an evaluation of clinical and radiologic factors. Otolaryngol Head Neck Surg 2000, 122(6):917-921. 144. Albuja-Cruz MB, Goldfarb M, Gondek SS, Allan BJ, Lew JI: Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm. J Surg Res 2013, 181(1):6-10. 145. Wharry LI, McCoy KL, Stang MT, Armstrong MJ, LeBeau SO, Tublin ME, Sholosh B, Silbermann A, Ohori NP, Nikiforov YE et al: Thyroid nodules (>/=4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg 2014, 38(3):614-621. 146. Mehanna R, Murphy M, McCarthy J, O'Leary G, Tuthill A, Murphy MS, Sheahan P: False negatives in thyroid cytology: impact of large nodule size and follicular variant of papillary carcinoma. Laryngoscope 2013, 123(5):1305-1309. 147. Giles WH, Maclellan RA, Gawande AA, Ruan DT, Alexander EK, Moore FD, Jr., Cho NL: False negative cytology in large thyroid nodules. Ann Surg Oncol 2015, 22(1):152-157. 148. Pinchot SN, Al-Wagih H, Schaefer S, Sippel R, Chen H: Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg 2009, 144(7):649-655. 149. Porterfield JR, Jr., Grant CS, Dean DS, Thompson GB, Farley DR, Richards ML, Reading CC, Charboneau JW, Vollrath BK, Sebo TJ: Reliability of benign fine needle aspiration cytology of large thyroid nodules. Surgery 2008, 144(6):963-968; discussion 968-969. 150. Raj MD, Grodski S, Woodruff S, Yeung M, Paul E, Serpell JW: Diagnostic lobectomy is not routinely required to exclude malignancy in thyroid nodules greater than four centimetres. ANZ J Surg 2012, 82(1-2):73-77. 151. Rosario PW, Salles DS, Bessa B, Purisch S: Low false-negative rate of cytology in thyroid nodules >or= 4 cm. Arq Bras Endocrinol Metabol 2009, 53(9):1143-1145. 152. Kuru B GN, Gulcelik MA, Dincer H: The false-negative rate of fine-needle aspiration cytology for diagnosing thyroid carcinoma in thyroid nodules. Langenbeck's Archives of Surgery 2010, 395:6. 153. Shrestha M, Crothers BA, Burch HB: The impact of thyroid nodule size on the risk of malignancy and accuracy of fine-needle aspiration: a 10-year study from a single institution. Thyroid 2012, 22(12):1251-1256. 154. Bestepe N, Ozdemir D, Tam AA, Dellal FD, Kilicarslan A, Parlak O, Ersoy R, Cakir B: Malignancy risk and false-negative rate of fine needle aspiration cytology in thyroid nodules >/=4.0 cm. Surgery 2016, 160(2):405-412. 155. Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, Benson CB, Doubilet PM, Cibas ES, Barletta J et al: Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 2013, 98(2):564-570. 156. Koo DH, Song K, Kwon H, Bae DS, Kim JH, Min HS, Lee KE, Youn YK: Does Tumor Size Influence the Diagnostic Accuracy of Ultrasound-Guided Fine-Needle Aspiration Cytology for Thyroid Nodules? Int J Endocrinol 2016, 2016:3803647. 157. Shi H, Bobanga I, McHenry CR: Are large thyroid nodules classified as benign on fine needle aspiration more likely to harbor cancer? Am J Surg 2017, 213(3):464-466. 158. Godazandeh G, Kashi Z, Zargarnataj S, Fazli M, Ebadi R, Kerdabadi EH: Evaluation the Relationship Between Thyroid Nodule Size with Malignancy and Accuracy of Fine Needle Aspiration Biopsy (FNAB). Acta Inform Med 2016, 24(5):347-350. 159. McHenry CR, Huh ES, Machekano RN: Is nodule size an independent predictor of thyroid malignancy? Surgery 2008, 144(6):1062-1068; discussion 1068-1069. 160. Magister MJ, Chaikhoutdinov I, Schaefer E, Williams N, Saunders B, Goldenberg D: Association of Thyroid Nodule Size and Bethesda Class With Rate of Malignant Disease. JAMA Otolaryngol Head Neck Surg 2015, 141(12):1089-1095. 161. Ucler R, Usluogullari CA, Tam AA, Ozdemir D, Balkan F, Yalcin S, Kiyak G, Ersoy PE, Guler G, Ersoy R et al: The diagnostic accuracy of ultrasound-guided fine-needle aspiration biopsy for thyroid nodules three centimeters or larger in size. Diagn Cytopathol 2015, 43(8):622-628. 162. Cavallo A, Johnson DN, White MG, Siddiqui S, Antic T, Mathew M, Grogan RH, Angelos P, Kaplan EL, Cipriani NA: Thyroid Nodule Size at Ultrasound as a Predictor of Malignancy and Final Pathologic Size. Thyroid 2017, 27(5):641-650. 163. Jinih M, Faisal F, Abdalla K, Majeed M, Achakzai AA, Heffron C, McCarthy J, Redmond HP: Association between thyroid nodule size and malignancy rate. Ann R Coll Surg Engl 2020, 102(1):43-48. 164. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H: Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008, 93(3):809-814. 165. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA: Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006, 91(11):4295-4301. 166. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A et al: Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004, 89(1):163-168. 167. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S: Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009, 5(1):35-44. 168. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS: The Diagnosis and Management of Thyroid Nodules: A Review. JAMA 2018, 319(9):914-924. 169. Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, Jung HK, Choi JS, Kim BM, Kim EK: Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011, 260(3):892-899. 170. Moon HJ, Kwak JY, Kim MJ, Son EJ, Kim EK: Can vascularity at power Doppler US help predict thyroid malignancy? Radiology 2010, 255(1):260-269. 171. Salmaslioglu A, Erbil Y, Dural C, Issever H, Kapran Y, Ozarmagan S, Tezelman S: Predictive value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter. World J Surg 2008, 32(9):1948-1954. 172. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM: Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002, 87(5):1941-1946. 173. Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M: An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009, 94(5):1748-1751. 174. Tae HJ, Lim DJ, Baek KH, Park WC, Lee YS, Choi JE, Lee JM, Kang MI, Cha BY, Son HY et al: Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid 2007, 17(5):461-466. 175. Shimura H, Haraguchi K, Hiejima Y, Fukunari N, Fujimoto Y, Katagiri M, Koyanagi N, Kurita T, Miyakawa M, Miyamoto Y et al: Distinct diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: a multicenter study. Thyroid 2005, 15(3):251-258. 176. Rago T, Santini F, Scutari M, Pinchera A, Vitti P: Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab 2007, 92(8):2917-2922. 177. Petersen M, Schenke SA, Firla J, Croner RS, Kreissl MC: Shear Wave Elastography and Thyroid Imaging Reporting and Data System (TIRADS) for the Risk Stratification of Thyroid Nodules-Results of a Prospective Study. Diagnostics (Basel) 2022, 12(1). 178. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM: Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 2007, 3(3):260-269. 179. Hartl DM, Chami L, Al Ghuzlan A, Leboulleux S, Baudin E, Schlumberger M, Travagli JP: Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. Ann Surg Oncol 2009, 16(9):2602-2608. 180. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R: Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003, 97(1):90-96. 181. Chen W, Parsons M, Torigian DA, Zhuang H, Alavi A: Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun 2009, 30(3):240-244. 182. Nishimori H, Tabah R, Hickeson M, How J: Incidental thyroid "PETomas": clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake. Can J Surg 2011, 54(2):83-88. 183. Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, Lumbroso J, Travagli JP, Hartl D, Baudin E et al: Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid 2012, 22(2):165-172. 184. Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A: Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid 1998, 8(1):15-21. 185. Baloch ZW, Tam D, Langer J, Mandel S, LiVolsi VA, Gupta PK: Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. Diagn Cytopathol 2000, 23(6):425-429. 186. Cibas ES, Ali SZ: The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017, 27(11):1341-1346. 187. Cibas ES, Ali SZ, Conference NCITFSotS: The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol 2009, 132(5):658-665. 188. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K et al: Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol 2016, 2(8):1023-1029. 189. Song SJ, LiVolsi VA, Montone K, Baloch Z: Pre-operative features of non-invasive follicular thyroid neoplasms with papillary-like nuclear features: An analysis of their cytological, Gene Expression Classifier and sonographic findings. Cytopathology 2017, 28(6):488-494. 190. Mito JK, Alexander EK, Angell TE, Barletta JA, Nehs MA, Cibas ES, Krane JF: A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience. Cancer Cytopathol 2017, 125(11):854-864. 191. Chandler JB, Colunga M, Prasad ML, Callender GG, Quinn C, Chhieng D, Adeniran AJ: Identification of distinct cytomorphologic features in the diagnosis of NIFTP at the time of preoperative FNA: Implications for patient management. Cancer Cytopathol 2017, 125(11):865-875. 192. Liu X, Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Larsen PR, Cho NL, Nehs MA, Ruan DT et al: Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis. Thyroid 2016, 26(2):256-261. 193. Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, Diggans J, Friedman L, Kennedy GC, Kloos RT et al: A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med 2013, 159(5):325-332. 194. Roth MY, Witt RL, Steward DL: Molecular testing for thyroid nodules: Review and current state. Cancer 2018, 124(5):888-898. 195. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM et al: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16(2):109-142. 196. Sacks WL, Bose S, Zumsteg ZS, Wong R, Shiao SL, Braunstein GD, Ho AS: Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy. Cancer Cytopathol 2016, 124(10):722-728. 197. Armstrong MJ, Yang H, Yip L, Ohori NP, McCoy KL, Stang MT, Hodak SP, Nikiforova MN, Carty SE, Nikiforov YE: PAX8/PPARgamma rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid 2014, 24(9):1369-1374. 198. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G et al: Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008, 9(6):543-549. 199. Samija I, Matesa N, Tadinac S, Jukic T: Quantitative Analysis of Galectin-3 Expression in Benign and Malignant Thyroid Nodules. Acta Clin Croat 2020, 59(Suppl 1):25-31. 200. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT et al: Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011, 96(11):3390-3397. 201. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, Di Santo A, Caruso G, Carli AF, Brilli L et al: Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010, 95(3):1365-1369. 202. Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E: Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg 2010, 34(11):2589-2594. 203. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, Moore P, Andruss B, Labourier E: Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Thyroid 2014, 24(10):1479-1487. 204. Xing M, Haugen BR, Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013, 381(9871):1058-1069. 205. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP et al: Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014, 120(23):3627-3634. 206. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, LeBeau SO, Ohori NP, Seethala RR et al: Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid 2015, 25(11):1217-1223. 207. Taye A, Gurciullo D, Miles BA, Gupta A, Owen RP, Inabnet WB, 3rd, Beyda JN, Marti JL: Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. Surgery 2018, 163(1):97-103. 208. Eszlinger M, Bohme K, Ullmann M, Gorke F, Siebolts U, Neumann A, Franzius C, Adam S, Molwitz T, Landvogt C et al: Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany. Thyroid 2017, 27(3):402-411. 209. Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, Hallanger-Johnson JE, Otto KJ, Rogers KD, Centeno BA et al: Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer 2017, 24(3):127-136. 210. Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Callenberg K, Santana-Santos L, Gooding WE, Yip L, Ferris RL, Nikiforov YE: Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 2018, 124(8):1682-1690. 211. Cancer Genome Atlas Research N: Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014, 159(3):676-690. 212. Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF et al: The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med 2015, 13:184. 213. Najafian A, Noureldine S, Azar F, Atallah C, Trinh G, Schneider EB, Tufano RP, Zeiger MA: RAS Mutations, and RET/PTC and PAX8/PPAR-gamma Chromosomal Rearrangements Are Also Prevalent in Benign Thyroid Lesions: Implications Thereof and A Systematic Review. Thyroid 2017, 27(1):39-48. 214. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ et al: Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012, 367(8):705-715. 215. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR: Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab 2014, 99(1):119-125. 216. Angell TE, Frates MC, Medici M, Liu X, Kwong N, Cibas ES, Kim MI, Marqusee E: Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up. J Clin Endocrinol Metab 2015, 100(11):E1477-1483. 217. Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW: Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2011, 96(11):E1719-1726. 218. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R et al: A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 2012, 18(7):2032-2038. 219. Lithwick-Yanai G, Dromi N, Shtabsky A, Morgenstern S, Strenov Y, Feinmesser M, Kravtsov V, Leon ME, Hajduch M, Ali SZ et al: Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears. J Clin Pathol 2017, 70(6):500-507. 220. Carpi A, Nicolini A: The role of large-needle aspiration biopsy in the preoperative selection of palpable thyroid nodules: a summary of principal data. Biomed Pharmacother 2000, 54(6):350-353. 221. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 7th ed. . New York: Springer 2010. 222. Song YS, Lim JA, Choi H, Won JK, Moon JH, Cho SW, Lee KE, Park YJ, Yi KH, Park DJ et al: Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 2016, 122(9):1370-1379. 223. Redman R, Zalaznick H, Mazzaferri EL, Massoll NA: The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. Thyroid 2006, 16(1):55-60. 224. Moon HJ, Kwak JY, Choi YS, Kim EK: How to manage thyroid nodules with two consecutive non-diagnostic results on ultrasonography-guided fine-needle aspiration. World J Surg 2012, 36(3):586-592. 225. Choi YS, Hong SW, Kwak JY, Moon HJ, Kim EK: Clinical and ultrasonographic findings affecting nondiagnostic results upon the second fine needle aspiration for thyroid nodules. Ann Surg Oncol 2012, 19(7):2304-2309. 226. Greer MA, Astwood EB: Treatment of simple goiter with thyroid. J Clin Endocrinol Metab 1953, 13(11):1312-1331. 227. Ross DS: Thyroid hormone suppressive therapy of sporadic nontoxic goiter. Thyroid 1992, 2(3):263-269. 228. Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL: Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 1990, 336(8709):193-197. 229. Castro MR, Caraballo PJ, Morris JC: Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 2002, 87(9):4154-4159. 230. Wemeau JL, Caron P, Schvartz C, Schlienger JL, Orgiazzi J, Cousty C, Vlaeminck-Guillem V: Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab 2002, 87(11):4928-4934. 231. Biondi B, Wartofsky L: Treatment with thyroid hormone. Endocr Rev 2014, 35(3):433-512. 232. Berghout A, Wiersinga WM, Drexhage HA, van Trotsenburg P, Smits NJ, van der Gaag RD, Touber JL: The long-term outcome of thyroidectomy for sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1989, 31(2):193-199. 233. Bistrup C, Nielsen JD, Gregersen G, Franch P: Preventive effect of levothyroxine in patients operated for non-toxic goitre: a randomized trial of one hundred patients with nine years follow-up. Clin Endocrinol (Oxf) 1994, 40(3):323-327. 234. Bonnema SJ, Nielsen VE, Hegedus L: Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. Eur J Endocrinol 2004, 150(4):439-445. 235. Manders JM, Corstens FH: Radioiodine therapy of euthyroid multinodular goitres. Eur J Nucl Med Mol Imaging 2002, 29 Suppl 2:S466-470. 236. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM: Radioiodine treatment of multinodular non-toxic goitre. BMJ 1993, 307(6908):828-832. 237. Graf H, Fast S, Pacini F, Pinchera A, Leung A, Vaisman M, Reiners C, Wemeau JL, Huysmans D, Harper W et al: Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab 2011, 96(5):1368-1376. 238. Zingrillo M, Torlontano M, Chiarella R, Ghiggi MR, Nirchio V, Bisceglia M, Trischitta V: Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid 1999, 9(8):763-767. 239. Papini E, Guglielmi R, Bizzarri G, Pacella CM: Ultrasound-guided laser thermal ablation for treatment of benign thyroid nodules. Endocr Pract 2004, 10(3):276-283. 240. Stan MN, Papaleontiou M, Schmitz JJ, Castro MR: Nonsurgical Management of Thyroid Nodules: The Role of Ablative Therapies. J Clin Endocrinol Metab 2022, 107(5):1417-1430. 241. Tulecke MA, Wang HH: ThinPrep for cytologic evaluation of follicular thyroid lesions: correlation with histologic findings. Diagn Cytopathol 2004, 30(1):7-13. 242. Liu Z, Lin Y, Cao Y, Hu H, Wei Y, Zhang Z, Lin S, Guo B: Swin Transformer: Hierarchical Vision Transformer using Shifted Windows. In.; 2021: arXiv:2103.14030. 243. Kornelius E, Lo SC, Huang CN, Yang YS: The Risk of Thyroid Cancer in Patients with Thyroid Nodule 3 Cm Or Larger. Endocr Pract 2020, 26(11):1286-1290. 244. Perrier ND, Brierley JD, Tuttle RM: Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2018, 68(1):55-63. 245. Xi X, Wang Y, Gao L, Jiang Y, Liang Z, Ren X, Gao Q, Lai X, Yang X, Zhu S et al: Establishment of an Ultrasound Malignancy Risk Stratification Model for Thyroid Nodules Larger Than 4 cm. Front Oncol 2021, 11:592927. 246. Shayganfar A, Hashemi P, Esfahani MM, Ghanei AM, Moghadam NA, Ebrahimian S: Prediction of thyroid nodule malignancy using thyroid imaging reporting and data system (TIRADS) and nodule size. Clin Imaging 2020, 60(2):222-227. 247. Schiffmann L, Kostev K, Kalder M: Association between various thyroid gland diseases, TSH values and thyroid cancer: a case-control study. J Cancer Res Clin Oncol 2020, 146(11):2989-2994. 248. Mekraksakit P, Rattanawong P, Karnchanasorn R, Kanitsoraphan C, Leelaviwat N, Poonsombudlert K, Kewcharoen J, Dejhansathit S, Samoa R: Prognosis of Differentiated Thyroid Carcinoma in Patients with Graves Disease: A Systematic Review and Meta-Analysis. Endocr Pract 2019, 25(12):1323-1337. 249. Staniforth JUL, Erdirimanne S, Eslick GD: Thyroid carcinoma in Graves' disease: A meta-analysis. Int J Surg 2016, 27:118-125. 250. Feldt-Rasmussen U: Hashimoto's thyroiditis as a risk factor for thyroid cancer. Curr Opin Endocrinol Diabetes Obes 2020, 27(5):364-371. 251. J.H. M: Thyroid and Its Diseases. J B Lippincott Co, Philadelphia 1937:5. 252. Cappelli C, Braga M, De Martino E, Castellano M, Gandossi E, Agosti B, Cumetti D, Pirola I, Mattanza C, Cherubini L et al: Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer: experience at an endocrine center in Italy. Surg Today 2006, 36(2):125-130. 253. Pacini F, Elisei R, Di Coscio GC, Anelli S, Macchia E, Concetti R, Miccoli P, Arganini M, Pinchera A: Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest 1988, 11(2):107-112. 254. Gerenova J, Buysschaert M, de Burbure CY, Daumerie C: Prevalence of thyroid cancer in Graves' disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Intern Med 2003, 14(5):321-325. 255. Ozaki O, Ito K, Kobayashi K, Toshima K, Iwasaki H, Yashiro T: Thyroid carcinoma in Graves' disease. World J Surg 1990, 14(3):437-440; discussion 440-431. 256. Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K, Ito K: Recent outcome of Graves' disease patients with papillary thyroid cancer. Eur J Endocrinol 2007, 157(3):325-329. 257. Tamatea JA, Tu'akoi K, Conaglen JV, Elston MS, Meyer-Rochow GY: Thyroid cancer in Graves' disease: is surgery the best treatment for Graves' disease? ANZ J Surg 2014, 84(4):231-234. 258. Chao TC, Lin JD, Chen MF: Surgical treatment of thyroid cancers with concurrent Graves disease. Ann Surg Oncol 2004, 11(4):407-412. 259. Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA: Thyroidectomy remains an effective treatment option for Graves' disease. Am J Surg 2006, 191(3):400-405. 260. Phitayakorn R, McHenry CR: Incidental thyroid carcinoma in patients with Graves' disease. Am J Surg 2008, 195(3):292-297; discussion 297. 261. Wei S, Baloch ZW, LiVolsi VA: Thyroid carcinoma in patients with Graves' disease: an institutional experience. Endocr Pathol 2015, 26(1):48-53. 262. Boutzios G, Vasileiadis I, Zapanti E, Charitoudis G, Karakostas E, Ieromonachou P, Karatzas T: Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' Disease. Thyroid 2014, 24(2):347-354. 263. Pellegriti G, Mannarino C, Russo M, Terranova R, Marturano I, Vigneri R, Belfiore A: Increased mortality in patients with differentiated thyroid cancer associated with Graves' disease. J Clin Endocrinol Metab 2013, 98(3):1014-1021. 264. Gabriele R, Letizia C, Borghese M, De Toma G, Celi M, Izzo L, Cavallaro A: Thyroid cancer in patients with hyperthyroidism. Horm Res 2003, 60(2):79-83. 265. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH: The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer. N Engl J Med 1988, 318(12):753-759. 266. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357(9255):539-545. 267. Dailey ME, Lindsay S, Skahen R: Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955, 70(2):291-297. 268. Resende de Paiva C, Gronhoj C, Feldt-Rasmussen U, von Buchwald C: Association between Hashimoto's Thyroiditis and Thyroid Cancer in 64,628 Patients. Front Oncol 2017, 7:53. 269. Lai X, Xia Y, Zhang B, Li J, Jiang Y: A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk. Oncotarget 2017, 8(37):62414-62424. 270. Moon S, Chung HS, Yu JM, Yoo HJ, Park JH, Kim DS, Park YJ: Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies. Endocrinol Metab (Seoul) 2018, 33(4):473-484. 271. Jankovic B, Le KT, Hershman JM: Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 2013, 98(2):474-482. 272. Nagayama Y: Thyroid Autoimmunity and Thyroid Cancer - The Pathogenic Connection: A 2018 Update. Horm Metab Res 2018, 50(12):922-931. 273. Ruf J, Carayon P, Lissitzky S: Various expressions of a unique anti-human thyroglobulin antibody repertoire in normal state and autoimmune disease. Eur J Immunol 1985, 15(3):268-272. 274. Cappelli C, Pirola I, Gandossi E, Rotondi M, Lombardi D, Casella C, Marini F, Saullo M, Agosti B, Di Lodovico E et al: Could Serum TSH Levels Predict Malignancy in Euthyroid Patients Affected by Thyroid Nodules with Indeterminate Cytology? Int J Endocrinol 2020, 2020:7543930. 275. Kratky J, Jezkova J, Kosak M, Vitkova H, Bartakova J, Mraz M, Lukas J, Limanova Z, Jiskra J: Positive Antithyroid Antibodies and Nonsuppressed TSH Are Associated with Thyroid Cancer: A Retrospective Cross-Sectional Study. Int J Endocrinol 2018, 2018:9793850. 276. Lee IS, Hsieh AT, Lee TW, Lee TI, Chien YM: The Association of Thyrotropin and Autoimmune Thyroid Disease in Developing Papillary Thyroid Cancer. Int J Endocrinol 2017, 2017:5940367. 277. Negro R, Valcavi R, Toulis KA: Incidental thyroid cancer in toxic and nontoxic goiter: Is TSH associated with malignanCy rate? Results of a meta-analysis. Endocr Pract 2013, 19(2):212-218. 278. Ma J, Wu F, Jiang T, Zhao Q, Kong D: Ultrasound image-based thyroid nodule automatic segmentation using convolutional neural networks. Int J Comput Assist Radiol Surg 2017, 12(11):1895-1910. 279. Hoang JK, Middleton WD, Farjat AE, Teefey SA, Abinanti N, Boschini FJ, Bronner AJ, Dahiya N, Hertzberg BS, Newman JR et al: Interobserver Variability of Sonographic Features Used in the American College of Radiology Thyroid Imaging Reporting and Data System. AJR Am J Roentgenol 2018, 211(1):162-167. 280. Acharya UR, Swapna G, Sree SV, Molinari F, Gupta S, Bardales RH, Witkowska A, Suri JS: A review on ultrasound-based thyroid cancer tissue characterization and automated classification. Technol Cancer Res Treat 2014, 13(4):289-301. 281. Russakovsky O, Deng J, Su H, Krause J, Satheesh S, Ma S, Huang Z, Karpathy A, Khosla A, Bernstein M et al: ImageNet Large Scale Visual Recognition Challenge. In.; 2014: arXiv:1409.0575. 282. Ma J, Wu F, Zhu J, Xu D, Kong D: A pre-trained convolutional neural network based method for thyroid nodule diagnosis. Ultrasonics 2017, 73:221-230. 283. Tsantis S, Dimitropoulos N, Cavouras D, Nikiforidis G: A hybrid multi-scale model for thyroid nodule boundary detection on ultrasound images. Comput Methods Programs Biomed 2006, 84(2-3):86-98. 284. Chang CY, Chen, S. J., Tsai, M. F.: Application of support-vector-machine-based method for feature selection and classification of thyroid nodules in ultrasound images. Pattern Recognition 2010, 43(10):13. 285. Stib MT, Pan I, Merck D, Middleton WD, Beland MD: Thyroid Nodule Malignancy Risk Stratification Using a Convolutional Neural Network. Ultrasound Q 2020, 36(2):164-172. 286. Ko SY, Lee JH, Yoon JH, Na H, Hong E, Han K, Jung I, Kim EK, Moon HJ, Park VY et al: Deep convolutional neural network for the diagnosis of thyroid nodules on ultrasound. Head Neck 2019, 41(4):885-891. 287. Swin Transformer: Hierarchical Vision Transformer using Shifted Windows [https://arxiv.org/abs/2103.14030v1?ref=hackernoon.com] 288. Zhang H, Wu C, Zhang Z, Zhu Y, Lin H, Zhang Z, Sun Y, He T, Mueller J, Manmatha R et al: ResNeSt: Split-Attention Networks. In.; 2020: arXiv:2004.08955. 289. Attention is all you need [https://arxiv.org/abs/1706.03762] 290. Dai Y, Gao Y, Liu F: TransMed: Transformers Advance Multi-Modal Medical Image Classification. Diagnostics (Basel) 2021, 11(8). 291. Ren S, He K, Girshick R, Sun J: Faster R-CNN: Towards Real-Time Object Detection with Region Proposal Networks. In.; 2015: arXiv:1506.01497. 292. Jégou S, Drozdzal M, Vazquez D, Romero A, Bengio Y: The One Hundred Layers Tiramisu: Fully Convolutional DenseNets for Semantic Segmentation. In.; 2016: arXiv:1611.09326. 293. Lakhani P, Sundaram B: Deep Learning at Chest Radiography: Automated Classification of Pulmonary Tuberculosis by Using Convolutional Neural Networks. Radiology 2017, 284(2):574-582. 294. Cicero M, Bilbily A, Colak E, Dowdell T, Gray B, Perampaladas K, Barfett J: Training and Validating a Deep Convolutional Neural Network for Computer-Aided Detection and Classification of Abnormalities on Frontal Chest Radiographs. Invest Radiol 2017, 52(5):281-287. 295. Rajpurkar P, Irvin J, Zhu K, Yang B, Mehta H, Duan T, Ding D, Bagul A, Langlotz C, Shpanskaya K et al: CheXNet: Radiologist-Level Pneumonia Detection on Chest X-Rays with Deep Learning. In.; 2017: arXiv:1711.05225. 296. Prevedello LM, Erdal BS, Ryu JL, Little KJ, Demirer M, Qian S, White RD: Automated Critical Test Findings Identification and Online Notification System Using Artificial Intelligence in Imaging. Radiology 2017, 285(3):923-931. 297. Lee H, Tajmir S, Lee J, Zissen M, Yeshiwas BA, Alkasab TK, Choy G, Do S: Fully Automated Deep Learning System for Bone Age Assessment. J Digit Imaging 2017, 30(4):427-441. 298. Larson DB, Chen MC, Lungren MP, Halabi SS, Stence NV, Langlotz CP: Performance of a Deep-Learning Neural Network Model in Assessing Skeletal Maturity on Pediatric Hand Radiographs. Radiology 2018, 287(1):313-322. 299. Kamnitsas K, Ledig C, Newcombe VFJ, Simpson JP, Kane AD, Menon DK, Rueckert D, Glocker B: Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation. Med Image Anal 2017, 36:61-78. 300. Iandola FN, Han S, Moskewicz MW, Ashraf K, Dally WJ, Keutzer K: SqueezeNet: AlexNet-level accuracy with 50x fewer parameters and <0.5MB model size. In.; 2016: arXiv:1602.07360. 301. Howard AG, Zhu M, Chen B, Kalenichenko D, Wang W, Weyand T, Andreetto M, Adam H: MobileNets: Efficient Convolutional Neural Networks for Mobile Vision Applications. In.; 2017: arXiv:1704.04861. 302. Liu YI, Kamaya A, Desser TS, Rubin DL: A bayesian network for differentiating benign from malignant thyroid nodules using sonographic and demographic features. AJR Am J Roentgenol 2011, 196(5):W598-605. 303. Wu H, Deng Z, Zhang B, Liu Q, Chen J: Classifier Model Based on Machine Learning Algorithms: Application to Differential Diagnosis of Suspicious Thyroid Nodules via Sonography. AJR Am J Roentgenol 2016, 207(4):859-864. 304. Chi J, Walia E, Babyn P, Wang J, Groot G, Eramian M: Thyroid Nodule Classification in Ultrasound Images by Fine-Tuning Deep Convolutional Neural Network. J Digit Imaging 2017, 30(4):477-486. 305. Dosovitskiy A, Beyer L, Kolesnikov A, Weissenborn D, Zhai X, Unterthiner T, Dehghani M, Minderer M, Heigold G, Gelly S et al: An Image is Worth 16x16 Words: Transformers for Image Recognition at Scale. In.; 2020: arXiv:2010.11929. 306. Thomas J, Haertling T: AIBx, Artificial Intelligence Model to Risk Stratify Thyroid Nodules. Thyroid 2020, 30(6):878-884. 307. Assocation AM: Code of ethics of the American Medical Association. Asa McFarland, Concord NH 1850. 308. Murray B: Informed consent: what must a physician disclose to a patient? Virtual Mentor 2012, 14(7):563-566. 309. Balint M: The Doctor's Therapeutic Function. Lancet 1965, 1(7397):1177-1180. 310. Brock DW: The ideal of shared decision making between physicians and patients. Kennedy Inst Ethics J 1991, 1(1):28-47. 311. Braddock CH, 3rd, Edwards KA, Hasenberg NM, Laidley TL, Levinson W: Informed decision making in outpatient practice: time to get back to basics. JAMA 1999, 282(24):2313-2320. 312. Metzl JM RM: Understanding the Symbolic Value of Medications: A Brief Review. Primary Psychiatry 2003, 10(7):4. 313. Lentacker A: The symbolic economy of drugs. Soc Stud Sci 2016, 46(1):140-156. 314. Tomes N: Patient empowerment and the dilemmas of late-modern medicalisation. Lancet 2007, 369(9562):698-700. 315. Beauchamp T CJ: Principles of biomedical ethics. Oxford University Press 2012. 316. Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA: Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 2008, 77(4):219-226. 317. Kehl KL, Landrum MB, Arora NK, Ganz PA, van Ryn M, Mack JW, Keating NL: Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care. JAMA Oncol 2015, 1(1):50-58. 318. Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA: Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin 2014, 64(6):377-388. 319. Stiggelbout AM, Pieterse AH, De Haes JC: Shared decision making: Concepts, evidence, and practice. Patient Educ Couns 2015, 98(10):1172-1179. 320. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, Tomson D, Dodd C, Rollnick S et al: Shared decision making: a model for clinical practice. J Gen Intern Med 2012, 27(10):1361-1367. 321. Beers E, Lee Nilsen M, Johnson JT: The Role of Patients: Shared Decision-Making. Otolaryngol Clin North Am 2017, 50(4):689-708. 322. Bomhof-Roordink H, Gartner FR, Stiggelbout AM, Pieterse AH: Key components of shared decision making models: a systematic review. BMJ Open 2019, 9(12):e031763. 323. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, Shong YK: Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004, 60(1):21-28. 324. Smith-Bindman R, Lebda P, Feldstein VA, Sellami D, Goldstein RB, Brasic N, Jin C, Kornak J: Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study. JAMA Intern Med 2013, 173(19):1788-1796. 325. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C: Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer 1993, 71(12):4022-4029. 326. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR et al: Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005, 237(3):794-800. 327. Middleton WD, Teefey SA, Reading CC, Langer JE, Beland MD, Szabunio MM, Desser TS: Multiinstitutional Analysis of Thyroid Nodule Risk Stratification Using the American College of Radiology Thyroid Imaging Reporting and Data System. AJR Am J Roentgenol 2017, 208(6):1331-1341. 328. Middleton WD, Teefey SA, Reading CC, Langer JE, Beland MD, Szabunio MM, Desser TS: Comparison of Performance Characteristics of American College of Radiology TI-RADS, Korean Society of Thyroid Radiology TIRADS, and American Thyroid Association Guidelines. AJR Am J Roentgenol 2018, 210(5):1148-1154. 329. Ha EJ, Na DG, Baek JH, Sung JY, Kim JH, Kang SY: US Fine-Needle Aspiration Biopsy for Thyroid Malignancy: Diagnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules. Radiology 2018, 287(3):893-900. 330. Oda H, Miyauchi A, Ito Y, Yoshioka K, Nakayama A, Sasai H, Masuoka H, Yabuta T, Fukushima M, Higashiyama T et al: Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. Thyroid 2016, 26(1):150-155. 331. Singh Ospina NM BD, Hargraves I, Barb D, Subbarayan S, Srihari A, Wang S, Maraka S, Bylund CL, Treise D, Montori V, Brito JP: Development and pilot testing of a conversation aid to support the evaluation of patients with thyroid nodules. Clin Endocrinol (Oxf) 2021. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/91332 | - |
dc.description.abstract | 目的:目前甲狀腺結節使用超音波掃描分類系統去做分析非常耗時耗力且主觀。人工智慧系統(Artificial intelligence; AI)已被可以使用來增加預測甲狀腺結節惡性率的精準度。這研究主要目的是想要用目前最先進的Swin 變形分類器去對甲狀腺結節做分類。
方法:前瞻性地收集了臺中榮民總醫院2019年1月至2021年6月接受甲狀腺結節細針穿刺的超音波影像。總共有139位病患有甲狀腺惡性結節,有 235位病患是良性的甲狀腺結節當對照組。這些收集的超音波影像會用Swin-T 和ResNeSt50模組去對甲狀腺結節做分析。 結果:相較於良性結節的甲狀腺病患,有甲狀腺惡性結節的病患傾向於較年輕且男性居多。Swin-T的平均敏感度跟特異度分別為82.46%和84.29%。ResNeSt50的平均敏感度跟特異度分別為72.51%和77.14%。接受者操作特性曲線(ROC)分析指出曲線下方的面積(AUC),Swin-T為0.91,高於ResNeSt50曲線下方的面積0.82。麥內瑪檢定評估Swin-T和ResNeSt50的表現發現Swin-T有意義的比ResNeSt50的表現好。 結論:Swin-T 分類器對於醫師和有任何大小甲狀腺結節的病患,協助醫病共享決策是一個有用的工具,特別是在超音波影像特徵有高度惡性風險的甲狀腺結節。Swin-T 分類器對於分類甲狀腺結節,相較於目前先進的影像相似演算法也有著一致性的較佳的表現。 | zh_TW |
dc.description.abstract | Purpose: The current ultrasound scan classification system for thyroid nodules is time-consuming, labor-intensive and subjective. Artificial intelligence (AI) has been shown to increase the accuracy of predicting the malignancy rate of thyroid nodules. This study aims to demonstrate the state-of-the-art Swin Transformer classifier to classify thyroid nodules.
Methods: Ultrasound images were collected prospectively from patients who received fine-needle aspiration biopsy for thyroid nodules at Taichung Veterans Hospital, Taichung, Taiwan, from January 2019 to June 2021. A total of 139 patients with malignant thyroid nodules were enrolled while 235 patients with benign nodules served as controls. Images were fed to Swin-T and ResNeSt50 model to classify the thyroid nodules. Results: Patients with malignant nodules tend to be younger and male gender compared to those with benign nodules. The average sensitivity and specificity of Swin-T were 82.46% and 84.29%, respectively. The average sensitivity and specificity of ResNeSt50 were 72.51% and 77.14%, respectively. Receiver operating characteristics (ROC) analysis revealed that the area under the curve (AUC) of Swin-T was higher (AUC=0.91) than that of ResNeSt50 (AUC=0.82). The McNemar test evaluating performance between Swin-T and ResNeSt50 showed that Swin-T had significantly better performance than ResNeSt50. Conclusion: Swin-T classifier can be a useful tool in helping shared decision making between physicians and patients with thyroid nodules of any size, particularly in those with high-risk characteristics of sonographic patterns. The Swin-T classifier had consistently better performance classifying thyroid nodules when compared with current state-of-the-art image similarity algorithm. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-12-20T16:31:55Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-12-20T16:31:55Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | Table of Contents
口試委員會審定書 II 誌謝…………………………………………………………………………………..III 中文摘要…………………………………………………………………..…………IV 英文摘要……………………………………………………………………………...V Table of contents……………………………………………………………………VII List of tables…………………………………………………………………..…….XI List of figures………………………………………………………………………XIV Chapter 1. Introduction………………………………………………........................1 1.1 The anatomy and functional images of the thyroid gland………………..…..1 1.1.1 Ultrasonogrpahy…………………..…………………………………..2 1.1.2 Scintigraphy…………….……………………………………….……9 1.1.3 Computed Tomography, CT………………………………………...15 1.1.4 Magnetic Resonance Imaging, MRI….……………………….……..19 1.1.5 Positron emission tomography, PET…………..………………….…24 1.1.6 Summary…..……………………………………………...................31 Chapter 2. Nontoxic thyroid goiter and thyroid nodular disease…………………….34 2.1 Definition…………………………………………………………………...34 2.2 Epidemiology of goiter……………………………………………………...34 2.3 Etiology and pathophysiology of diffuse goiter..…………………………...35 2.4 Etiology of nodular thyroid goiter...………………………………………...36 2.5 Pathophysiology of nodular thyroid goiter………………………………...47 2.5.1 Hyperplasia of the thyroid gland………………………………….....47 2.5.2 Higher serum clearance of iodide…………………………………...48 2.5.3 Negative effects of oxidative stress on thyroid hormone systhesis….49 2.5.4 Nodular transformation, pregression to nontoxic nodular goiter........50 2.6 Natural history of goiter and thyoid nodules...……………………………...54 2.7 Clinical manifestations of goiter and nodules……….……………………...56 2.8 How to approach thyroid nodular disease………………...……………...…59 2.9 Association of thyroid nodule size and malignancy………….......................67 2.10 Evaluation of patients with nodular disease………………………..……...70 2.11 Fine-needle aspiration biopsy, FNAB…………………………………..…79 2.12 Molecular diagnotics of thyroid nodules….…………………………….....84 2.12.1 Limitions of thyroid cytopathology and histopathology……..…….86 2.12.2 Development of thyroid molecular testing…………...………….…88 Chapter 3. Approach to nontoxic diffuse goiter and nodular thyroid disease……..…96 3.1 Nontoxic diffuse goiter…………………………………………………..….96 3.2 Nontoxic nodular goiter…………...………………………………..……....98 Chapter 4. Material and methods………………………………………….………..104 4.1 Subjects……………………………………………….……….……….….104 4.2 Ethical consideration…………………………………………….…….….105 4.3 Image database………………………………………………….……..…105 4.4 Swin Transformer and ResNeSt50 model……………………………....…106 4.5 Statistical analysis…………………………………………….………...…110 Chapter 5. Results……………………………………………………………...…....111 5.1 Baseline characteristics, nodule size, and serum biochemical tests in patients with benign or malignant nodules…..........................................................................111 5.2 Image database analysis………………………………………………..….113 Chapter 6. Discussion…………………………………………………………….…116 6.1 Contribution………………………………………………...…………...…116 6.2 Whether thyroid nodule size is a factor in determining aspiration or surgery………………………………………………………………………………117 6.3 The association of thyroid-stimulating hormone and thyroid nodule malignancy risk……………………………………………………………………..119 6.4 Thyroid nodules and artificial intelligence………………………………...123 6.5 Shared decision-making, SDM……………….…………………...………129 6.5.1 Evolution of decision-making patterns………………...………..….129 6.5.2 Components of a shared decision-making…..………………….…..133 6.5.3 The role of shared decision-making in the management of thyroid nodules……………………………………………………………………………...134 6.6 The role of artificial ingelligence in thyroid nodules...............................…135 6.7 Limitations………………………………………………………………...137 Chapter 7. Conclusion……………………………………………………………..139 Reference……………………………………………………………………………139 | - |
dc.language.iso | en | - |
dc.title | 以一個先進的深度學習系統去分層高危險甲狀腺結節 | zh_TW |
dc.title | Stratifying High Risk Thyroid Nodules Using a Novel Deep Learning System | en |
dc.type | Thesis | - |
dc.date.schoolyear | 112-1 | - |
dc.description.degree | 博士 | - |
dc.contributor.oralexamcommittee | 曾宇鳳;傅楸善;王俊興;蔡尚峰 | zh_TW |
dc.contributor.oralexamcommittee | Yu-Feng Tseng;Chiou-Shann Fuh;Jun-Sing Wang;Shang-Feng Tsai | en |
dc.subject.keyword | 甲狀腺結節,超音波,人工智慧,Swin變形器,ResNeSt50, | zh_TW |
dc.subject.keyword | Thyroid nodules,ultrasonography,Artificial Intelligence,Swin Transformer,ResNeSt50, | en |
dc.relation.page | 169 | - |
dc.identifier.doi | 10.6342/NTU202304484 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-12-08 | - |
dc.contributor.author-college | 電機資訊學院 | - |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | - |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-112-1.pdf 目前未授權公開取用 | 9.1 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。